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Abstract Rheumatoid arthritis (RA) is a systemic inflammatory disorder that manifests 
predominantly in the synovial joint, where it causes a chronic inflammatory process, 
leading to early osteoarticular destructions. These destructions are progressive and 
irreversible, generating a significant functional deficiency. During the last years, the 
diagnostic approach of RA has focused on early arthritis. Early arthritis can develop into 
established RA or another established arthropathy, like systemic lupus erythematosus or 
psoriatic arthritis. It can have a spontaneous resolution or may remain undifferentiated 
for indefinite periods of time.  
The management of early arthritis has changed considerably in the past few years, 
under the influence of new concepts of diagnosis and new effective therapies. The 
treatment goal of early arthritis should now be the clinical remission and prevention of 
joint destruction. Methotrexate is the first line of therapy, used to treat early arthralgia 
and to reverse or limit impending exacerbation to RA. Biological treatment is used as a 
second line therapy in patients with severe disease who do not respond or have a 
contraindication to disease-modifying antirheumatic drugs (DMARDs). Patients with 
early arthritis should usually be identified and directed to rheumatologists to confirm the 
presence of arthritis, and to establish the correct diagnosis plus to initiate the proper 
treatment strategies.   
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Highlights ✓ Patients with early arthritis should be referred to the rheumatologist, to be able to establish 
a fast diagnosis and prompt therapy.   
✓ The management of early arthritis should include not only drug treatment but also specific 
medical education. 
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Introduction 
Rheumatoid arthritis (RA) is a systemic 
inflammatory disorder that manifests predominantly in 
the synovial joint, where it causes a chronic 
inflammatory process, leading to osteoarticular 
destructions. These destructions occur early and are 
progressive and irreversible, generating a significant 
functional deficiency. RA is frequently accompanied by 
significant and varied systemic manifestations and could 
reduce life expectancy due to several complications. 
 RA is the most common inflammatory rheumatic 
illness. The articular and systemic consequences have a 
significant impact on patients’ quality of life and 
prognosis, but also on the healthcare systems. The 
disease has considerable heterogeneity and can have 
different forms: mild, non-erosive, sometimes with 
spontaneous remission, or severe, rapidly progressive 
forms, with significant and irreversible osteoarticular 
destructions.  
 For a better prognosis of patients with RA, 
establishing an earlier diagnosis and initiating treatment 
is critical. In clinical practice, diagnosis of early arthritis 
has become an important step. During the last years, the 
diagnostic approach of RA is focused on early arthritis. 
Inflammatory arthritis is one of the most common 
pathological findings in clinical rheumatology. 
Identifying the main disease can be very difficult, 
especially in an early stage. In clinical practice, an early 
inflammatory arthritis is often undifferentiated (1). 
Early arthritis can often lead to established RA or other 
arthropathies, such as systemic lupus erythematosus or 
psoriatic arthritis.  
Most of the symptoms in early arthritis remain 
undifferentiated for indefinite periods of time. For a 
better evaluation of the diagnosis of arthritis, 
recognizing the inflammatory arthritis is necessary. The 
next step is to search for a definite diagnosis and to 
estimate the risk of developing persistent arthritis. An 
optimal therapeutic strategy is essential (2, 3). Although 
the prognosis of early arthritis is still difficult to assess, 
a combination of clinical, laboratory, and radiological 
findings may help to predict patients’ outcomes. 
Discussions 
Etiology 
 Numerous factors influence the onset of RA, the 
majority being common with those involved in the 
appearance of early arthritis. The exact cause of the RA 
is unknown; it is considered a disease with multifactorial 
complex determinism (4). It can have multiple risk 
factors involving the host organism (e.g. genetic, 
hormonal factors), environmental factors (smoking, 
infections - Porphyromonas gingivalis, Ebstein Barr 
virus, Mycoplasma pneumoniae), obesity, or socio-
economic status (5). 
 The evolutive phases of rheumatoid arthritis are 
influenced by the presence of the risk factors: genetics 
(HLA-DRB1, PTPN22, STAT4, PAD14), smoking or 
bacteria like Porfiromonas gingivalis or Porfiromonas 
copri (6). 
 These factors can precede the pre-clinical 
rheumatoid arthritis phase (no symptoms), which 
involves the systemic autoimmunity, with high levels of 
rheumatoid factor, proinflammatory cytokines, high 
sensitive C-reactive protein (CRP), and the positivity of 
anti-citrullinated protein antibodies (ACPA) and anti-
protein carbamylated antibodies (7). 
Clinical manifestations 
 The early rheumatoid arthritis phase involves 
nonspecific signs and symptoms, including articular 
ones. The definite rheumatoid arthritis phase fulfills the 
classification criteria, with systematic and articular 
manifestations, high inflammatory markers such as C-
reactive protein (CRP) or erythrocyte sedimentation rate 
(ESR), high rheumatoid factor, and positive anti-
citrullinated protein antibodies (ACPA) (8). 
 The diagnosis is based on the European League 
Against Rheumatism (EULAR) defined characteristics, 
patients with arthralgia being at risk for RA (9). These 
parameters are used in patients with arthralgia without 
clinical arthritis and without other diagnosis or other 
explanation for the arthralgia. The diagnosis of RA 
involves a history of joint symptoms with recent onset 
(duration less than 1 year) (10); symptoms localized in 
metacarpo-phalangeal joints; duration of morning 
stiffness more than 60 minutes; most severe symptoms 
present more in the early morning than the rest of the 
day; presence of a first degree relative with RA; first 
movement difficulties; and positive squeeze test of 
metacarpophalangeal joints (11).  
 The undefined arthritis is approached differently by 
two important rheumatology groups’ associations: the 
Norfolk group defines it as two or more swollen joints, 
for no less than two weeks, and the Leiden group sees it 
as one or more swollen joints, diagnosed by a 
rheumatologist, that have no other cause (12, 13). 
 Regarding the symptoms, there is a series of 
nonspecific symptoms, like fatigue, undefined illness, 
nonspecific muscular pain, mood disorders, or sub fever. 
The articular symptoms include stiffness with variable 
duration, non-characteristic to inflammatory pain, 
nonspecific joint pain, symptoms of palindromic 
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rheumatism and dysfunctional symptoms that can affect 
the daily activities (14). 
 The connective-diseases screening questionnaire 
and the rheumatoid arthritis questionnaire have high 
specificity and sensibility. In a retrospective meta-
analysis that included studies published between 1940-
2012, using as inclusion criteria the symptoms of RA at 
the onset of the disease, the authors have found that the 
most frequent symptoms were joint swelling, local pain 
and sensitivity, joint fatigue, fatigability, and asthenia, 
all symptoms having an emotional impact (15). 
Paraclinical diagnosis  
 Paraclinical diagnosis is based on laboratory tests 
and imaging characteristics. Although there are no 
specific biological markers or certain imaging tests for 
early arthritis, because studies are still ongoing, most of 
them are common for RA and early arthritis. The same 
meta-analysis cited previously found positivity of anti-
citrullinated protein antibodies (ACPA) before 
rheumatoid factor (FR) titers increased at a shorter 
interval before diagnosis, a positive titer of anti-
citrullinated protein antibodies (ACPA), alpha tumor 
necrosis factor (TNF alpha), interleukins 1,2 and 15 (IL 
1, IL2, IL 15), and gamma interferon (15). 
 A brief report showed the presence of 
anticarbamilated protein antibodies (anti-CarP) and their 
role in predicting the development of RA (16). These are 
relatively new antibodies, studies showing that 16% of 
patients with RA have anti-CarP IgG even in the absence 
of anti-citrullinated protein antibodies (ACPA). They 
are associated with a severe destructive disease at the 
articular level; they can be detected up to 4 years prior 
to RA (16). 
 The anti-ribonucleoprotein A2/ anti RA22 nuclear 
heterologous antibodies are present in 20-30% of 
patients diagnosed with AR, but also in systemic lupus 
erythematosus (SLE) or juvenile idiopathic arthritis 
(JIA) (17). The epitope recognition is different in RA 
patients, the specificity for RA is approximately 90%; it 
is not associated with radiological progression. Serum 
level equals the disease activity, with the tendency to 
normalize during remission. 
Imaging in early arthritis 
 Imaging has a very important role in the diagnosis 
of RA. However, in early arthritis, imaging may not be 
as useful as the clinical examination, due to the features 
that tend to appear late, especially at ultrasonography. 
Imaging is important in order to confirm the further 
installation of RA. 
 Ultrasonography (US): A study combining routine 
assessment and power Doppler ultrasonography was 
performed in order to predict the progression to RA from 
early-onset undifferentiated arthritis (18). The study 
involved 149 patients with undifferentiated arthritis, 
with early onset <16 weeks. The examined joints were 
radiocarpal, metacarpophalangeal joints 2-5, and 
interphalangeal joints 2-5 bilateral. The results showed 
that the power Doppler signal present at more than 3 
joints increases the probability of progression to AR to 
41% and the positivity of anti-citrullinated protein 
antibodies (ACPA) or rheumatoid factor increases the 
probability to 65% (19). 
 Magnetic resonance imaging (MRI): In early 
arthritis, we can use RAMRIS (Rheumatoid Arthritis 
MRI Score) to observe the synovitis, erosion and bone 
edema. Synovitis of interphalangeal joints is an 
independent predictor for RA, with high relative risk. 
Bone edema of metacarpo-phalangeal and radiocarpal 
could be independent predictors (20). 
Treatment of early arthritis    
The management of an early arthritis has changed 
substantially in the past few years as the result of new 
concepts proposed for diagnosis and new effective 
therapies. The treatment goal of such early arthritis 
should now be represented by clinical remission and 
prevention of joint destruction. The 2016 update of the 
European League Against Rheumatism (EULAR) 
recommendations for the management of early arthritis 
(March 2017) includes 3 general principles and 12 
recommendations (21). 
Principles: 
• The first principle indicates that the decisions taken 
in the management of the disease should be based on the 
relationship between patients and rheumatologist. 
• The second principle highly recommends that 
rheumatologists be the first specialists to examine the 
patient with early arthritis. 
• The third principle highlights the steps to the 
definitive diagnosis of early arthritis that should be 
made only after a full history and clinical examination 
and that should guide the laboratory analysis and 
additional investigations. 
Recommendations 
• Recommendation 1 strongly advises that the patient 
be seen early and examined by a rheumatologist, no later 
than 6 weeks after joints symptoms appear. 
• Recommendation 2 places clinical examination first, 
with the condition of confirmation by ultrasonography. 
• Recommendation 3 indicates a series of parameters, 
as the number of painful and swollen joints, the level of 
acute phase reactants, the rheumatoid factor or anti-
citrullinated protein antibodies titer, and the imaging 
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changes, that must be evaluated in patients with 
undifferentiated early arthritis. 
• Recommendation 4 strongly indicates that treatment 
with disease-modifying antirheumatic drugs 
(DMARDs) should start no later than 3 months after the 
joint symptoms appear, even if patients do not fulfill the 
classification criteria for a rheumatologic inflammatory 
disease. 
• Recommendation 5 highlights that methotrexate 
should be used as first line therapy in patients at risk for 
persistent disease with no contraindication for MTX. 
• Recommendation 6 strongly recommends 
nonsteroidal anti-inflammatory drugs (NSAIDs) as a 
therapy that should be used carefully, only for a short 
period of time and at the lowest effective dose. 
• Recommendation 7 presents the beneficial effects of 
corticosteroids on pain, swelling, and structural 
progression reduction, but recommend corticosteroids 
only as a temporary adjuvant treatment, no longer than 
6 months. 
• Recommendation 8 advises taking into account the 
comorbidities and the side effects of disease-modifying 
antirheumatic drugs (DMARDs) in the therapeutic 
management of early arthritis. 
• Recommendation 9 indicates some variables, 
including assessments of the number of swollen and 
painful joints, visual analog scale (VAS), C-reactive 
protein (CRP) and erythrocyte sedimentation rate 
(ESR), be used in monitoring the disease activity, and 
that these should be performed between 1 and 3 months 
until reaching the therapeutic target. 
• Recommendation 10 takes into consideration 
rehabilitation exercises and therapies that could be used 
as adjuvants for treatment. 
• Recommendation 11 highly recommends primary 
prevention in patients with early arthritis, including 
quitting smoking, dental care, weight control, or 
vaccination. 
• Recommendation 12 highlight the importance that 
different information and education programs could 
have on patients in order to help them maintain work 
capacity and to cope with the pain and the functional 
deficit. 
 Treatment with nonsteroidal anti-inflammatory 
drugs (NSAIDs), if used long term, is a major risk factor 
for renal injury, via direct nephrotoxic effects, with 
acute tubular necrosis. Kidney injury may lead to 
chronic kidney disease, with the necessity of chronic 
dialysis (22, 23). The renal function may be affected also 
by other mechanisms, such as obstruction of the urinary 
tract, which may manifest over time with chronic kidney 
disease, usually well tolerated by the patients, due to 
slow installation (24, 25). Use of NSAIDs as analgesics 
in the postoperative period, for example, may further 
deteriorate the renal function (26-28). Treatment with 
NSAIDSs should be used with caution in patients with 
cardiovascular comorbidities (29, 30). 
Disease-modifying antirheumatic drugs (DMARDs) 
treatment 
 The conventional anti-rheumatic drugs (synthetic 
disease-modifying/ csDMARDs) have been shown to 
diminish disease progression in chronic inflammatory 
arthritis, such as RA and psoriatic arthritis (PsA) (31). 
Furthermore, biological DMARDs have demonstrated 
rapid and sustained disease control associated with a 
reduction of joint destruction. 
 Methotrexate (MTX) is the first line therapy used to 
treat early arthralgia, to reverse or limit impending 
exacerbation to RA (32). A randomized, placebo-
controlled study (2015) was done in patients with no 
ACPA/ FR, without clinical arthritis, arthralgia <1 year 
(suspected clinical arthralgia), MRI inflammation, 
treated with 120 mg methylprednisolone + MTX / 
placebo for 12 months (33). Results showed an 
important influence of the treatment on the installation 
of clinical arthritis (33). 
 A prospective, placebo-controlled, double-blind 
study (2012) in 110 patients with undifferentiated 
arthritis using MTX 15 mg/ week, for 1 year showed the 
improvement and reduction of the progression of 
arthralgia, especially in ACPA positive patients (34). 
 Corticosteroid treatment. Corticosteroids improve 
clinical and radiological outcomes. Therapy with 
systemic corticosteroids should be temporary due to the 
risk of side effects, including weight gain, hypertension, 
diabetes, cataract, and osteoporosis, which justify 
careful monitoring and appropriate prevention (35). 
Dexamethasone has demonstrated effect on 
autoantibody levels in early arthritis (36). In 2010, in a 
case-control study on 83 ACPA positive patients with 
arthralgia, without signs of undifferentiated arthritis, 
using 2 administrations of Dexamethasone 100 mg at 6-
week intervals, the results showed ACPA and FR 
titration reduction, but no delay in the progression of the 
disease to clinically non-differentiated arthritis (37). 
Antimalarial treatment. Although the current data 
could not show an important effect of 
hydroxychloroquine (HCQ) in early arthritis or RA, as 
it has in systemic lupus erythematosus (SLE), some 
studies have established its possible use in specific 
patients. 
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 Hydroxychloroquine. It seems that the antimalarial 
therapy can be used in case of arthritis progressing to 
RA or other connective tissue diseases in patients with 
palindromic rheumatism. In a retrospective study on 113 
patients diagnosed with palindromic rheumatism and 33 
with RA, this therapy reduced progression to RA in 69% 
of patients treated with HCQ (38, 39). 
 Biological treatment. This kind of treatment opened 
a new era in the management of many inflammatory 
diseases. In early arthritis and RA, it is used as a second 
line therapy in patients with severe disease who do not 
respond or who have a contraindication to DMARDs, 
the first line of therapy still remaining the methotrexate. 
 Rituximab. The PRAIRI study (2016) showed the 
prevention of RA by B cell-directed therapy in the 
earliest phase of the disease. In this randomized, 
placebo-controlled, double-blind study, on 81 patients 
during 29 months, without clinically obvious arthritis, 
with rheumatoid factor, ACPA positive, elevated levels 
of C-reactive protein, subclinical US/ MRI synovitis, 
with 40 patients using 1000 mg rituximab/ 40 placebo 
(premedication with 100 mg methylprednisolone), 
results showed that patients using rituximab developed 
RA at 24 months vs 12 months with placebo (40). 
 Infliximab did not demonstrate surprising results. In 
a double-blind, placebo-controlled study on 17 patients 
with undifferentiated arthritis <12 months (10 using 
infliximab, 7 placebo), this treatment showed a C-
reactive protein reduction after 14 weeks, with HAQ 
(Health Assessment Questionnaire) improvement (40). 
In the 26th week: no statistical significance DAS 28 
(Disease Activity Score), with only a small reduction in 
morning stiffness. In week 52, all patients (Interferon 
users+ placebo) had developed RA. 
 Abatacept. Studies using this biological treatment 
are yet in progress. The APPIPRA study aims to show 
the reverse of subclinical inflammation. Begun in 
December 2017 and estimated to finish in December 
2018, this study uses a randomized, placebo-controlled 
design on anti-citrullinated protein antibodies (ACPA) 
positive patients with joint pain, without clinically 
obvious arthritis, comparing 125 mg Abatacept vs 
placebo (41, 42). 
Conclusions 
Patients with early arthritis should be referred to the 
rheumatologist in order to recognize the presence of 
arthritis and to confirm the potential diagnosis. Prompt 
initiation of treatment is essential. The management of 
early arthritis should include drug treatment associated 
with medical education (43). Comorbidities in patients 
with early arthritis play an important role for the 
therapeutical decision (44-46). The shared decision 
between patient and rheumatologist plays an important 
role for allied healthcare professionals. 
Though no cure for rheumatoid arthritis is available, 
patients can take positive steps to delay some of the 
more severe joints damage and allow them to continue 
to live a long, healthy life.  
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